TABLE 1.
Influence way | Effect target | Activate/Inhibit | References | |
---|---|---|---|---|
Estrogen | ATP-P2X7R-NLRP3 | P2X7R | Inhibit | Gorodeski (2004) |
ACE-angiotensin II-AT1-NLRP3 | ACE | Inhibit | Brosnihan et al. (1999), Kisley et al. (1999), Wu et al. (2003) | |
AT1 | ||||
ACE2-angiotensin (1–7)-NLRP3 | ACE2 | Inhibit | Bukowska et al. (2017) | |
RANKL-JNK- NLRP3 phosphorylation | RANKL | Inhibit | Srivastava et al. (2001) | |
PKD3-NLRP3 phosphorylation | PKD3 | Inhibit | Borges et al. (2015) | |
PP2A-NLRP3 dephosphorylation | PP2A | Inhibit | Ueda et al. (2013) | |
HSP27-NLRP3 | HSP27 | Inhibit | Rayner et al. (2008), Rayner et al. (2009) | |
Progesterone | HMGB1-NLRP3 | HMGB1 | Inhibit | Espinosa-Garcia et al. (2020) |
Testosterone | ROS-NLRP3 | ROS | Activate | Chignalia et al. (2012) |
ATP-P2X7R-testosterone-NLRP3 | Testosterone | Activate | Foresta et al. (1996), Antonio et al. (2009), Zhang et al. (2017) | |
NLRP3 | NLRP3 | Activate | Ma et al. (2020) | |
mROS-NLRP3 | mROS | Activate | Alves et al. (2020) | |
Androgen | ACE2-angiotensin (1–7)-NLRP3 | ACE2 | Inhibit | La Vignera et al. (2020) |